Medipost to open US clinical trials on stem cell drug for Alzheimer’s disease – The Investor
Korea Biomedical Review |
Medipost to open US clinical trials on stem cell drug for Alzheimer's disease
The Investor [THE INVESTOR] Medipost said on Feb. 5 it has received approval from the US Food and Drug Administration to begin early-stage clinical studies of its stem cell-based therapy for Alzheimer's disease. The Seoul-based company plans to evaluate the safety … Medipost gets FDA nod for Alzheimer treatment |
